Navigation Links
Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published today in the New England Journal of Medicine ("A National Survey of Physician-Industry Relationships") on the extent of doctor and pharmaceutical company relationships, highlights the need for profession-wide and public policy reforms promoted by The Prescription Project. The article concludes that the existing, voluntary PhRMA (Pharmaceutical Research and Manufacturers of America) Code isn't working.

The Prescription Project offers solutions to this continuing crisis by outlining specific suggestions for academic medical centers, physician leadership and policy makers to end industry influence on medicine:

"The fact that 94% of physicians have relationships with pharmaceutical companies is a clear barrier to a trusting and effective doctor patient relationship. Academic medical centers and professional medical societies must take the lead in protecting public trust in the medical profession by adopting reforms," said David J. Rothman, PhD, Associate Director of The Prescription Project and president of Institute on Medicine as a Profession, which funded the NEJM study.

"Though the financial ties are extensive, the change we are advocating for can be made and must be made. One can look to the example of several leading academic medical centers to see that this approach can work. We now need a profession-wide adoption of those policies at all hospitals, physician practices and professional medical societies," Rothman continued.

"Legislators across the country are concerned about the influence of the pharmaceutical industry on doctors, and how it affects patient care and costs," said Rob Restuccia, Director of The Prescription Project. "Proposals to stem the tide of industry gifts and end data-mining are moving to the floors of state houses nationwide."

-- Today, New York legislators joined with national consumer and senior groups to introduce a pair of bills to end data-mining and restrict industry gifts.

-- Earlier this week, Minnesota state officials announced a joint effort with consumers and health groups there to strengthen the state's first-in-nation 1993 gift law.

-- Maine and Vermont legislators are debating gifts disclosure and data-mining bills now, and a hearing on an academic-detailing bill is scheduled in Maine next Monday.

"Our ability to support and strengthen coalitions in states like these is crucial to getting policies that preserve the doctor-patient trust in place," Restuccia said.

For more information, visit www.prescriptionproject.org .

Contact

for The Prescription Project
Diana Pisciotta, 617-784-5256
or
Terence Burke, 617-482-0042


'"/>




Related medicine technology :

1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
3. Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
4. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
5. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. MUSC Research Offers Hope for Those Resistant to Depression Treatment
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Antibiotics Dont Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... Dr. Edward Hebert is celebrating ... imagine doing anything else,” said Dr. Hebert. “I count my blessings daily for the ... with my patients is what I look forward to the most. The relationships I ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a tender and ... share with the others. “Grandpa's Visit” is the creation of published author, Beverly Brumfield, ... is much like the character in her book. She shares, “Mr. Rice is struggling ...
(Date:9/25/2017)... ... , ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the ... drinks, with the new NEXTY Gold Award at the Natural Products Expo East trade ... which is reserved for just those companies that hit high marks on the criteria ...
(Date:9/25/2017)... ... September 25, 2017 , ... Emerald Ash Borers kill Ash trees in as ... throughout the Philadelphia region. A video by Rob Nagy, ISA Certified Arborist at Giroud ... While several are dead or showing signs of decline from Emerald Ash Borers, two ...
(Date:9/24/2017)... ... ... Andrea Purcell, NMD, had an epiphany one evening. Four months pregnant, she sat sobbing at ... pregnancy was so hard. She wondered why no one talks about what it is really ... she decided to write what she wished her friends and colleagues could have told her: ...
Breaking Medicine News(10 mins):